Epithelial-mesenchymal transition (EMT) and TGF-β/Smad3 signaling axis dysregulation constitute critical drivers of CDK4/6 inhibitor resistance, enabling tumor cell plasticity and therapeutic evasion. The gene discussed is SMAD3; the disease is neoplasm.